Now Enrolling

Astrid StudyA clinical trial evaluating an oral medicine to potentially treat stress urinary incontinence (SUI)

Pipeline

Our lead product candidate is focused on stress urinary incontinence, which affects up to 35 percent of adult women. Learn about our pipeline »

News

April 16, 2018
GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting MORE »
April 9, 2018
GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence MORE »

Key Opinion Leader (KOL) Luncheon
09/28/17 12:00 p.m. ET
Webcast Presentation »
Key Opinion Leader (KOL) Luncheon Presentation [PDF] »
  • Information Request
  • Contact
  • Careers
Search
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • Stress Urinary Incontinence
    • Breast Cancer
    • Prostate Cancer
  • Diseases
    • Overview
    • Stress Urinary Incontinence
    • Breast Cancer
    • Prostate Cancer
  • Science
    • Overview
    • Selective Androgen Receptor Modulator (SARM)
      • The Potential Advantage of SARMs
      • SARMs in SUI
      • SARMs in Breast Cancer
    • Selective Androgen Receptor Degrader (SARD)
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Financial Reports
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Investor FAQs
    • IRS Form 8937
    • Contact Us
Developing hormone receptor-based medicines, for lif
© 2018 GTx, Inc. All Rights Reserved
  • Terms & Conditions
MENU
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • Stress Urinary Incontinence
    • Breast Cancer
    • Prostate Cancer
  • Diseases
    • Overview
    • Stress Urinary Incontinence
    • Breast Cancer
    • Prostate Cancer
  • Science
    • Overview
    • Selective Androgen Receptor Modulator (SARM)
      • The Potential Advantage of SARMs
      • SARMs in SUI
      • SARMs in Breast Cancer
    • Selective Androgen Receptor Degrader (SARD)
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Financial Reports
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Investor FAQs
    • IRS Form 8937
    • Contact Us